Fluoropyrrolopyridine compound and application thereof
Disclosed is a fluoropyrrolopyridine compound, and specifically disclosed is a compound represented by formula (II), an isomer or a pharmaceutically acceptable salt thereof.
1. A compound represented by formula (II) or a pharmaceutically acceptable salt thereof,
wherein,
ring A is
T 1 , T 2 , T 3 , T 4 and T 5 are each independently C, CH or N;
E 1 is O or S;
R 1 is each independently H or C 1-3 alkyl, wherein the C 1-3 alkyl is optionally substituted with 1, 2 or 3 R a ;
R 2 is each independently H or C 1-3 alkyl, wherein the C 1-3 alkyl is optionally substituted with 1, 2 or 3 R b ;
R 3 is H or C 1-3 alkyl;
R 4 is each independently H, C 1-3 alkyl, —O—C 1-3 alkyl or —S(O) 2 —C 1-3 alkyl, wherein the C 1-3 alkyl, —O—C 1-3 alkyl and —S(O) 2 —C 1-3 alkyl are each independently optionally substituted with 1, 2 or 3 R c ;
R a , R b and R c are each independently F, Cl, Br or I;
m is 1, 2 or 3.
2. The compound according to claim 1 or the pharmaceutically acceptable salt thereof, wherein the compound has the structure of formula (I-1) or (I-2)
wherein,
R 1 and R 2 are as defined above.
3. The compound according to claim 1 or the pharmaceutically acceptable salt thereof, wherein R 1 is each independently H or CH 3 , wherein the CH 3 is optionally substituted with 1, 2 or 3 R a .
4. The compound according to claim 3 or the pharmaceutically acceptable salt thereof, wherein R 1 is each independently H or CH 3 .
5. The compound according to claim 1 or the pharmaceutically acceptable salt thereof, wherein R 2 is each independently H or CH 3 , wherein the CH 3 is optionally substituted with 1, 2 or 3 R b .
6. The compound according to claim 5 or the pharmaceutically acceptable salt thereof, wherein R 2 is each independently H or CH 3 .
7. The compound according to claim 1 or the pharmaceutically acceptable salt thereof, wherein R 3 is each independently H or CH 3 .
8. The compound according to claim 1 or the pharmaceutically acceptable salt thereof, wherein R 4 is each independently H, CH 3 , —O—CH 3 or —S(O) 2 —CH 3 .
9. The compound according to claim 1 or the pharmaceutically acceptable salt thereof, wherein ring A is
10. The compound according to claim 9 or the pharmaceutically acceptable salt thereof, wherein ring A is
11. A compound represented by the following formula or a pharmaceutically acceptable salt thereof, and the compound is
12. A method for inhibiting ATR in a subject in need thereof, comprising: administering an effective amount of the compound according to claim 1 or the pharmaceutically acceptable salt thereof to the subject.